Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta

In recent years, a number of drugs have been approved for the treatment of cystic fibrosis (CF). Among them, newly released Trikafta, a combination of 3 drugs (VX-661/VX-445/VX-770), holds great promise to radically improve the quality of life for a large portion of patients with CF carrying 1 copy...

Descripción completa

Detalles Bibliográficos
Autores principales: Liessi, Nara, Pesce, Emanuela, Braccia, Clarissa, Bertozzi, Sine Mandrup, Giraudo, Alessandro, Bandiera, Tiziano, Pedemonte, Nicoletta, Armirotti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455125/
https://www.ncbi.nlm.nih.gov/pubmed/32673287
http://dx.doi.org/10.1172/jci.insight.138722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455125/
https://www.ncbi.nlm.nih.gov/pubmed/32673287
http://dx.doi.org/10.1172/jci.insight.138722

Ejemplares similares